- Email: [email protected]
FC042 An epidemiological survey about acne in a scholar population in France
S124
Free Communications
Nine patients had arthritis but only 3 of these had psoriatic arthropathy by definition. The low score in comparison to other series may be explained by 80% of the patients having a PAS1 score of less than 25%.
FCO40 Treatment of psoriasis vulgaris by cadmium laser - A preliminary - report . A. Zalewska’ , C. Peszyiiski-Drews*, L. Wolf *, A. Omulecki ’ . ‘Dermatology Department, Medical of tddf; University
*Laser
of
Diagnostics Eddi, Poland
and Therapy
Center;
University Technical
Psoriasis is a very common inflammatory skin disease showing a complex alteration of the skin immune system. It is postulated that different laser beams can influence different pathological processes which are responsible for occurrence of psoriatic lesions. Cadmium laser, which emits light at a wavelength of 441.6 nm was selected for this study, power of the laser was 22 mW, irradiation time 10 min. Laser treatment was administered everyday for 21 days (one session). Patients with stable, symmetrical, chronic plaque type psoriasis were recruited for the study. PAS1 score was evaluated at the beginning and at the end of the laser treatment. At the final assessment, performed 4 weeks after completing one session of laser treatment, patients recorded an improvement of about 60%. It is worth pointing out that the cadmium laser treatment in stable psoriasis could be regarded as a supplementary way of treatment.
1FC041 1 Comparative study of oral low-dose and high-dose isotretinoin in acne I. Lefaki, G. Karakatsanis, G. Vakali, E. Kapetis, G.Ch. Chaidemenos, R. Efthymiadou, A. Minas. State Hospital for
Skin and Venereal
Diseases,
Thessaloniki,
Greece
Clinical activity of oral isotretinoin in acne was first demonstrated with doses as high as 0.5-l mg/kgr* The low-dose schema consists of 10-20 mg/daily for 10-12 months to a total dose up to 120 mg/kgr*. (1). 64 patients with different types and grades of acne were divided into two treatment groups in a trial that compared low-dose oral isotretinoin 0.15-0.30 mg/kgr* versus high-dose isotretinoin 0.5-l mg/kgr*. The low dose group was treated for a period of lo-12 months to a cumulative dose of
[l] Kligman AM. Treating severe inflammatory acne: the last word. Cutis 57: 1,26-7, Jan 1996.
- General
Dermatology
FC042 An epidemiological survey about acne in a scholar population in France F. Daniel ’ , N. A&ret’, C. Beylot ’ , I. Bodokh ’ , M. Chivot ’ , B. Dreno ’ , P. Humbert ’ , J. Meynadier ’ , F. Poli ’ , P. Clerson *, R. Humbert*. ’ GREA (Groupe de Recherche et d’Etudes sur 1‘Acne’);
*Orgame’trie,
59800,
Lille,
France
An epidemiological survey regarding the prevalence and the type of lesions-of acne in a-schooi going population aged between 11 and 18 years old was conducted in November 1996. The population showed statistically significant differences for age and sex urban and rural residence, the level of sun-exposure between Northern and Southern France and the social class. 913 individuals were assessed by dermatologists and classified according to the ECLA scale. 72% of them had acne lesions, with a progression from 38% for the youngest people to nearly 90% for the oldest. The breakdown of the type of lesions, the modalities of treatment and the psychological impact of acne disease will be discussed.
FC043 Tazarotene 0.1% gel plus corticosteroid cream in the treatment of plaque psoriasis J. Sefton ’ , D.A. Lew-Kaya’ , M. Mierzwa’, A. Vasilopoulos’ J.C. Lue ’ , J.R. Gibson ’ . 1Allergan Skin Care Clinical Research
Br Development,
Irvine
,
CA, USA
Three hundred patients with plaque psoriasis participated in a multicenter, investigator-masked clinical comparison of tazarotene 0.1% gel plus a corticosteroid cream versus tazarotene 0.1% gel plus a placebo cream. Patients were randomly assigned to one of four treatment groups: 1) tazarotene gel plus a low-potency corticosteroid (fluocinolone acetonide 0.01% cream); 2) tazarotene gel plus a midpotency corticosteroid (mometasone furoate 0.1% cream); 3) tazarotene gel plus a high-potency corticosteroid (fluocinonide 0.05% cream); or 4) tazarotene gel plus a placebo cream. The assigned corticosteroid cream or the placebo cream was applied once daily in the morning, and tazarotene 0.1% gel was applied once daily in the evening. The treatment period was 12 weeks and was followed by a 4-week period of post-treatment evaluation. Patients were evaluated at baseline (week 0) and weeks 2, 4, 8, 12, and 16. The primary efficacy variables were severity of plaque elevation (graded on a scale from none to very severe) and global response (completely cleared to condition worsened). The combination of tazarotene and a topical corticosteroid provided for an optimized therapeutic regimen in the management of plaque psoriasis.
Free Communications
Nine patients had arthritis but only 3 of these had psoriatic arthropathy by definition. The low score in comparison to other series may be explained by 80% of the patients having a PAS1 score of less than 25%.
FCO40 Treatment of psoriasis vulgaris by cadmium laser - A preliminary - report . A. Zalewska’ , C. Peszyiiski-Drews*, L. Wolf *, A. Omulecki ’ . ‘Dermatology Department, Medical of tddf; University
*Laser
of
Diagnostics Eddi, Poland
and Therapy
Center;
University Technical
Psoriasis is a very common inflammatory skin disease showing a complex alteration of the skin immune system. It is postulated that different laser beams can influence different pathological processes which are responsible for occurrence of psoriatic lesions. Cadmium laser, which emits light at a wavelength of 441.6 nm was selected for this study, power of the laser was 22 mW, irradiation time 10 min. Laser treatment was administered everyday for 21 days (one session). Patients with stable, symmetrical, chronic plaque type psoriasis were recruited for the study. PAS1 score was evaluated at the beginning and at the end of the laser treatment. At the final assessment, performed 4 weeks after completing one session of laser treatment, patients recorded an improvement of about 60%. It is worth pointing out that the cadmium laser treatment in stable psoriasis could be regarded as a supplementary way of treatment.
1FC041 1 Comparative study of oral low-dose and high-dose isotretinoin in acne I. Lefaki, G. Karakatsanis, G. Vakali, E. Kapetis, G.Ch. Chaidemenos, R. Efthymiadou, A. Minas. State Hospital for
Skin and Venereal
Diseases,
Thessaloniki,
Greece
Clinical activity of oral isotretinoin in acne was first demonstrated with doses as high as 0.5-l mg/kgr* The low-dose schema consists of 10-20 mg/daily for 10-12 months to a total dose up to 120 mg/kgr*. (1). 64 patients with different types and grades of acne were divided into two treatment groups in a trial that compared low-dose oral isotretinoin 0.15-0.30 mg/kgr* versus high-dose isotretinoin 0.5-l mg/kgr*. The low dose group was treated for a period of lo-12 months to a cumulative dose of
[l] Kligman AM. Treating severe inflammatory acne: the last word. Cutis 57: 1,26-7, Jan 1996.
- General
Dermatology
FC042 An epidemiological survey about acne in a scholar population in France F. Daniel ’ , N. A&ret’, C. Beylot ’ , I. Bodokh ’ , M. Chivot ’ , B. Dreno ’ , P. Humbert ’ , J. Meynadier ’ , F. Poli ’ , P. Clerson *, R. Humbert*. ’ GREA (Groupe de Recherche et d’Etudes sur 1‘Acne’);
*Orgame’trie,
59800,
Lille,
France
An epidemiological survey regarding the prevalence and the type of lesions-of acne in a-schooi going population aged between 11 and 18 years old was conducted in November 1996. The population showed statistically significant differences for age and sex urban and rural residence, the level of sun-exposure between Northern and Southern France and the social class. 913 individuals were assessed by dermatologists and classified according to the ECLA scale. 72% of them had acne lesions, with a progression from 38% for the youngest people to nearly 90% for the oldest. The breakdown of the type of lesions, the modalities of treatment and the psychological impact of acne disease will be discussed.
FC043 Tazarotene 0.1% gel plus corticosteroid cream in the treatment of plaque psoriasis J. Sefton ’ , D.A. Lew-Kaya’ , M. Mierzwa’, A. Vasilopoulos’ J.C. Lue ’ , J.R. Gibson ’ . 1Allergan Skin Care Clinical Research
Br Development,
Irvine
,
CA, USA
Three hundred patients with plaque psoriasis participated in a multicenter, investigator-masked clinical comparison of tazarotene 0.1% gel plus a corticosteroid cream versus tazarotene 0.1% gel plus a placebo cream. Patients were randomly assigned to one of four treatment groups: 1) tazarotene gel plus a low-potency corticosteroid (fluocinolone acetonide 0.01% cream); 2) tazarotene gel plus a midpotency corticosteroid (mometasone furoate 0.1% cream); 3) tazarotene gel plus a high-potency corticosteroid (fluocinonide 0.05% cream); or 4) tazarotene gel plus a placebo cream. The assigned corticosteroid cream or the placebo cream was applied once daily in the morning, and tazarotene 0.1% gel was applied once daily in the evening. The treatment period was 12 weeks and was followed by a 4-week period of post-treatment evaluation. Patients were evaluated at baseline (week 0) and weeks 2, 4, 8, 12, and 16. The primary efficacy variables were severity of plaque elevation (graded on a scale from none to very severe) and global response (completely cleared to condition worsened). The combination of tazarotene and a topical corticosteroid provided for an optimized therapeutic regimen in the management of plaque psoriasis.